OncoGenex Pharmaceuticals Initiates An International, Randomized, Phase II Clinical Trial Evaluating OGX-427 In Advanced Bladder Cancer
Comments (0)Posts tagged: ogx
Comments (0)OncoGenex commences enrollment in OGX-427 Phase II trial for bladder cancer
OncoGenex Pharmaceuticals, Inc. announced today that it has initiated patient enrollment in a randomized, Phase II clinical trial evaluating OGX-427, an inhibitor of heat shock protein 27 (Hsp27), in patients with advanced bladder cancer.
Teva And OncoGenex Present Preclinical Data On The Activity Of Its Antisense Compound Custirsen (OGX-011/TV-1011) At The AACR Annual Meeting 2011
Teva Pharmaceutical Industries Ltd.(NASDAQ:TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that new preclinical data of their investigational compound custirsen (OGX-011/TV-1011) in castrate resistant prostate cancer (CRPC) were presented this week at the 102nd Annual Meeting of the AACR. These data provide additional evidence in support of the clinical ...
OncoGenex presents OGX-427 preclinical data in prostrate cancer at AACR meeting
OncoGenex Pharmaceuticals, Inc. announced today that preclinical data utilizing their pipeline compound OGX-427 was presented at the AACR 102nd Annual Meeting 2011.
OncoGenex Announces Data Highlighting OGX-427 At American Association Of Cancer Research (AACR) 102nd Annual Meeting 2011
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced yesterday (4th April) that preclinical data utilizing their pipeline compound OGX-427 was presented at the AACR 102nd Annual Meeting 2011. The study demonstrated the ability of OGX-427 to inhibit Heat Shock Protein 27 (Hsp27), a cell-survival protein believed to play an important role in ...
Isis Pharmaceuticals to Receive $10 Million From OncoGenex’ License of OGX-011 to Teva
CARLSBAD, Calif., Dec. 21 /- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI ) as a result of OncoGenex' license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a ...
OncoGenex’ OGX-011 receives additional FDA Fast Track Designation for treating metastatic prostate cancer
OncoGenex Pharmaceuticals, Inc. announced today that OGX-011, also known as custirsen sodium, received an additional Fast Track Designation from the U.S. Food & Drug Administration (FDA) for progressive metastatic prostate cancer in combination with first-line docetaxel treatment.
011, additional, cancer, designation, fast, fda, metastatic, ogx, oncogenex, prostate, receives, track, treating
OncoGenex Expands Clinical Development Of OGX-427 With A Phase 1 Clinical Trial In Bladder Cancer
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), announced that the first patient has been dosed in an open label, dose-escalation, Phase 1 clinical trial evaluating OGX-427 when administered directly into the bladder in patients with bladder cancer. This trial is separate from an ongoing Phase 1 trial of OGX-427 administered systemically ...
OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
BOTHELL, WA and VANCOUVER, Aug. 13 / OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ), today announced that the first patient has been dosed in an open label, dose-escalation, Phase 1 clinical trial evaluating OGX-427 when administered directly into the bladder in patients with bladder cancer. This trial is separate ...
OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
BOTHELL, WA, and VANCOUVER, Aug. 10 / OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer ...